Comparison of Modified and High Dose of Cisatracurium for Rapid Sequence Intubation
Keywords:
Cisatracurium, Rapid sequence intubation, hemodynamic Introduction,Abstract
Introduction: Rapid Sequence induction is a safe method of endotracheal intubation in emergency settings. Succinylcholine rapid onset of effect and ultrashort duration of action permitted rapid endotracheal intubation. To avoid Succinylcholine adverse effects, Cisatracurium at high dose is candidate.
Aim: to compare rapid sequence intubation conditions using modified and high dose of cisatracurium.
Methods: In a randomized, double-blind clinical trial 300 patients were enrolled in the study and randomly assigned to receive modified dose (0.3 mg/kg) Cisatracurium or high dose (0.4 mg/kg) Cisatracurium for intubation. Primary outcome was larygoscopy and intubation conditions including vocal cords movement and position and secondary outcome was hemodynamics during and after intubation. All data and train of four (TOF) were recorded at 0 to 5 min after drug administration. Intubation was performed at 90 min after drug administration when TOF=0.
Results: 300 patients were divided into 2 groups of 0.3 mg/kg and 0.4 mg/kg. Age, sex and weight were not significantly different between two groups of study. The onset time of complete neuromuscular blockade (TOF=0) were not significantly different between modified dose (85±22 seconds) and high dose (86±26 seconds) of Cisatracurium. Vocal cords movements were observed in 3 patients in modified dose group and 2 patients in high dose group which was not significantly different (p=0.082). Blood pressure and heart rate were not significantly different between two groups of study at any time points (p>0.05).
Conclusion: 0.3 versus 0.4 mg/kg cisatracurium had the same effect in providing appropriate laryngoscopy condition for rapid sequence intubation after 90 seconds. it is safer to use modified 0.3 mg/kg instead of 0.4 mg/kg cisatracurium to achieve acceptable condition for rapid sequence intubation.
Â
References
Thesleff S: Farmakologiska och kliniska forsok med L.T. I. (O,O-succinylcholine jodid). Nord Med 1951; 46:1045-1051
Foldes FF, McNall PG, Borrego-Hinojosa JM: Succinylcholine, a new approach to muscular relaxation in anaesthesiology. N Engl J Med 1952; 247:596-600.
Powell JN, Golby M: The pattern of potassium liberation following a single dose of suxamethonium in normal and uraemic rats. Br J Anaesth 1971; 43:662-668.
Schwartz DE, Kelly B, Caldwell JE, et al: Succinylcholine-induced hyperkalemic arrest in a patient with severe metabolic acidosis and exsanguinating hemorrhage. Anesth Analg 1992; 75:291-293.
Savarese JJ, Ali HH, Basta SJ, et al: The cardiovascular effects of mivacurium chloride (BW B1090U) in patients receiving nitrous oxide–opiate-barbiturate anesthesia. Anesthesiology 1989; 70:386-394.
Magorian T, Flannery KB, Miller RD: Comparison of rocuronium, succinylcholine, and vecuronium for rapid-sequence induction of anesthesia in adult patients. Anesthesiology 1993; 79:913-918.
Donati F, Meistelman C: A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs. J Pharmacokinet Biopharm 1991; 19:537-552.
Wright PM, Caldwell JE, Miller RD: Onset and duration of rocuronium and succinylcholine at the adductor pollicis and laryngeal adductor muscles in anesthetized humans. Anesthesiology 1994; 81:1110-1115.
Kim KS, Chung CW, Shin WJ.Cisatracurium neuromuscular block at the adductor pollicis and the laryngeal adductor muscles in humans. Br J Anaesth. 1999 Sep;83(3):483-4.
Plaud B, Debaene B, Lequeau F, et al: Mivacurium neuromuscular block at the adductor muscles of the larynx and adductor pollicis in humans. Anesthesiology 1996; 85:77-81.
Hemmerling TM, Schmidt J, Hanusa C, et al: Simultaneous determination of neuromuscular block at the larynx, diaphragm, adductor pollicis, orbicularis oculi and corrugator supercilii muscles. Br J Anaesth 2000; 85:856-860.
Doenicke AW, Czeslick E, Moss J, Hoernecke R.Onset time, endotracheal intubating conditions, and plasma histamine after cisatracurium and vecuronium administration. Anesth Analg. 1998 Aug;87(2):434-8.
Bowman WC, Rodger IW, Houston J, et al: Structure:action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anesthetized cat. Anesthesiology 1988; 69:57-62.
Kopman AF, Klewicka MM, Kopman DJ, Neuman GG: Molar potency is predictive of the speed of onset of neuromuscular block for agents of intermediate, short, and ultrashort duration. Anesthesiology 1999; 90:425-431.
Kirov K, Motamed C, Decailliot F, Behforouz N, Duvaldestin P.Comparison of the neuromuscular blocking effect of cisatracurium and atracurium on the larynx and the adductor pollicis. cta Anaesthesiol Scand. 2004 May;48(5):577-81.
El-Kasaby AM, Atef HM, Helmy AM, El-Nasr MA.Cisatracurium in different doses versus atracurium during general anesthesia for abdominal surgery. Saudi J Anaesth. 2010 Sep;4(3):152-7. doi: 10.4103/1658-354X.71571.
Meistelman C, Plaud B, Donati F: Rocuronium (ORG 9426) neuromuscular blockade at the adductor muscles of the larynx and adductor pollicis in humans. Can J Anaesth 1992; 39:665-669.
Lepage JY, Malinovsky JM, Malinge M, Lechevalier T, Dupuch C, Cozian A, Pinaud M, Souron R.Pharmacodynamic dose-response and safety study of cisatracurium (51W89) in adult surgical patients during N2O-O2-opioid anesthesia. Anesth Analg. 1996 Oct;83(4):823-9.
Lien CA, Belmont MR, Abalos A, Eppich L, Quessy S, Abou-Donia MM, Savarese JJ.The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology. 1995 May;82(5):1131-8.
Belmont MR, Lien CA, Quessy S, Abou-Donia MM, Abalos A, Eppich L, Savarese JJ.The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology. 1995 May;82(5):1139-45.
Downloads
Published
How to Cite
Issue
Section
License
- Papers must be submitted on the understanding that they have not been published elsewhere (except in the form of an abstract or as part of a published lecture, review, or thesis) and are not currently under consideration by another journal published by any other publisher.
- It is also the authors responsibility to ensure that the articles emanating from a particular source are submitted with the necessary approval.
- The authors warrant that the paper is original and that he/she is the author of the paper, except for material that is clearly identified as to its original source, with permission notices from the copyright owners where required.
- The authors ensure that all the references carefully and they are accurate in the text as well as in the list of references (and vice versa).
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Attribution-NonCommercial 4.0 International that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- The journal/publisher is not responsible for subsequent uses of the work. It is the author's responsibility to bring an infringement action if so desired by the author.